Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Cell Pathways |
---|---|
Information provided by: | OSI Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00036257 |
The purposes of this study are to determine a maximum tolerated dose and to evaluate the safety and efficacy of CP-461 in patients with Chronic Lymphocytic Leukemia.
Condition | Intervention | Phase |
---|---|---|
Chronic Lymphocytic Leukemia |
Drug: CP-461 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Florida | |
Cancer Centers of Florida | |
Orlando, Florida, United States, 32806 | |
United States, New York | |
Albany Regional Cancer Center | |
Albany, New York, United States, 12208 | |
United States, Texas | |
Mary Crowley Medical Research Center (US Oncology) | |
Dallas, Texas, United States, 75246 | |
Tyler Cancer Center | |
Tyler, Texas, United States, 75702 | |
United States, Washington | |
Cancer Care Northwest | |
Spokane, Washington, United States, 99218 |
Study ID Numbers: | OSI-461-010 |
Study First Received: | May 8, 2002 |
ClinicalTrials.gov Identifier: | NCT00036257 |
Health Authority: | United States: Food and Drug Administration |
Chronic Lymphocytic Leukemia Leukemia CLL |
Chronic lymphocytic leukemia Lymphatic Diseases Leukemia Leukemia, Lymphoid Immunoproliferative Disorders |
Leukemia, Lymphocytic, Chronic, B-Cell Leukemia, B-cell, chronic Lymphoproliferative Disorders Leukemia, B-Cell |
Neoplasms Neoplasms by Histologic Type Immune System Diseases |